A randomized, double-blind, placebo-controlled study to assess the efficacy of tocilizumab (TCZ) + non-biological DMARD in reducing synovitis as measured by magnetic resonance imaging (MRI) at 12 weeks after initiation of treatment in patients with moderate to severe rheumatoid arthritis (RA) with inadequate response to non-biological DMARDs.
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Tocilizumab (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms PORTRAIT
- Sponsors Roche
- 21 Apr 2012 Official Title amended as reported by European Clinical Trials Database record.
- 21 Apr 2012 Planned end date (30 Sep 2011) added as reported by European Clinical Trials Database.
- 21 Apr 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.